FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:393-395 July 24, 2003 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Punglia, R. S. PubMed Citation

Verification bias can influence the interpretation of the most important screening test for prostate cancer, measurement of prostate-specific antigen (PSA). Such bias arises when the presence or absence of prostate cancer has not been verified by prostate biopsy in all subjects in the screened population. In this issue of the Journal, Punglia et al. report on how verification bias alters the sensitivity and specificity of the PSA test, and how this bias can influence the clinical decision about whether to perform a biopsy of the prostate.¹ The problem has been recognized previously,^2,3 but Punglia et al. address it with the . . . [Full Text of this Article]

Source Information

From the Erasmus Medical Center, Rotterdam, the Netherlands.

This article has been cited by other articles:

• Blackstone, E. H., Lauer, M. S. (2004). Caveat emptor: The treachery of work-up bias. J. Thorac. Cardiovasc. Surg. 128: 341-344 [Full Text]  
• Morgentaler, A. (2004). A 66-Year-Old Man With Sexual Dysfunction. JAMA 291: 2994-3003 [Full Text]  
• Rhoden, E. L., Morgentaler, A. (2004). Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. NEJM 350: 482-492 [Full Text]